Philip Morris
Special Note to Investors
Fields
- Area
- WAKEHAM,HELMUT/KAROL SHARPE'S OFFICE
- Type
- REPT, OTHER REPORT
- Named Organization
- Cetus
- Polaroid
- Xerox
- Polaroid
- Request
- Stmn/R1-004
- Stmn/R1-150
- Master ID
- 1000229536/9811
Related Documents:- 1000229537-9544
- 1000229545-9550 Brief Synopsis
- 1000229551-9552 Introduction
- 1000229553-9555 Brief History of Cetus Financing
- 1000229556-9557
- 1000229561-9563 Special Note Regarding Founder's Stock
- 1000229567-9569 Board of Directors
- 1000229575-9580 Achievements of Cetus People
- 1000229581-9599 Present Cetus Activities
- 1000229600-9616 Research Plan
- 1000229617-9619 Patents
- 1000229621-9656 Debenture Purchase Agreement
- 1000229657-9661 the Cetus Story
- 1000229663-9667 Cloning Business: It's Growing Fast It's Growing Fast
- 1000229668 World Roundup
- 1000229669-9670 Latin Drive: Brazil Spends Millions to Put Alcohol in Cars and Save Oil
- 1000229671 Can US Reduce Imports with Gasoline? Some Say Yes, But Officials Are Dubious
- 1000229672-9673 Bacterial Insulin Production Hears Reality
- 1000229674 Business World
- 1000229675-9677 Who Should Play God?
- 1000229678 Schering Plough New York Analysts' Meeting December 7, 1977
- 1000229679 Indiana Standard Labels Purchase Offer Part of Move to Wider Technology Base
- 1000229680 Big Deal for Berkley Bugs
- 1000229681 Oil-Less World May Run on Bugs
- 1000229682-9685 Tinkering with Life
- 1000229686-9687 Set for Biology's New Revolution
- 1000229688 Little Black Box of Cetus
- 1000229689-9695 Industry Is Finding More Jobs for Microbes
- 1000229696-9701 Dup of Id 1000229657-9661
- 1000229702-9710 Recombinant Molecular Research at Cetus Corporation
- 1000229711-9715 New Cetus Antibiotic
- 1000229716-9720 Letter to the Shareholders
- 1000229721-9726 Letter to Shareholders
- 1000229727-9728 Letters to the Shareholders
- 1000229729-9730
- 1000229731-9734 Letter to the Shareholders
- 1000229735-9736 Letter to Shareholders
- 1000229737-9749 the Manipulation of Genes
- 1000229750-9770 Microbial Genetics and the Future of the Pharmaceutical Industry
- 1000229771-9774 Recombinant Dna: Fact and Fiction
- 1000229775-9778 Testomony of Ronald E Cape, Phd President, Cetus Corporation, Berkeley, California Before the House Subcommittee on Science, Research and Technology
- 1000229779-9797 Biosystems Poised for Growth
- 1000229798-9805 Testimony of Ronald E. Cape, Ph.D President, Cetus Corporation, Berkley, California Before the Senate Subcommittee on Science, Technology and Space
- 1000229806-9807 Statement of Ronald E. Cape, Ph.D President, Cetus Corporation, Berkeley, California Before A Special Joint Congressional Hearing in Conjunction with Oversight Hearings on Science and Technology Policy the Senate Subcommittee on Science, Technology and Space of the Commerce, Science and Transportation Committee Presiding, Senator Adlai Stevenson, III Washington, Dc
- 1000229808-9811 Statement of Ronald E. Cape, Ph.D. President, Cetus Corporation, Berkeley, California at the Annual Meeting of the American Association for the Advancement of Science Session on Recombinant Dna Public Health and Biomedical Research Policy Washington, D.C.
- Litigation
- Stmn/Produced
- Characteristic
- CONF, CONFIDENTIAL
- Site
- R37
- Date Loaded
- 05 Jun 1998
- UCSF Legacy ID
- ufo74e00
Document Images
Special Note to Prospective Investor(s)
Cetus is spearheading the creation of a totally new industry. Our ina- ,
bility to make predictions with certainty regarding which particular
applications of molecular biology will prove most profitable in no way
compromises the certainty that the revolution is real.* This very
uncertainty as to the specifics dictates that Cetus maintain and build
its leadership across a broad front - the leading edge of the field,
wherever it occurs. This we have continued to do, as an examination of
the scope of our projects, the physical reality and focus of our facili-
ties, and the breadth of our skills will readily.demonstrate. Far from
,putting all our eggs in one basket, we have many eggs and many baskets.
This, coupled with our ambitious and long-term aspirations, dictates
serious and long-term goals on the part of any investors. Cetus is not
a "get-rich-quick" scheme. It is not likely to make.sense to "go public,"
nor to sell out for quick gain. What, then, can,a,large investor expect?
t, n
First, an ongoing involvement with the highest-level of.excellence in a
field of profound economic importance,,,:possibly with significant direct
impact in an industry where the investor is="already irivolved. To de-
scribe this as a "window on the techriology";fails to do justice to the
special nature of Cetus. v o~~oy~
In many instances, as reflected in our,.current ctivities, this canlead
to an "inside track" or a very'early awareness of potential projects or
specific new developments that could be of profound interest to the in-
vesting company. Needlessto say,"the terms of any commercial relation-
ship must be worked out in a conventional negotiating framework. No two
_Cetus-client relationships are identical.
o A major benefit to a large industrial investor is the opportunity to
work with Cetus anticipating,'and later integrating into its own product
and process strategy, developments in molecular biology of special sig-
nificance to the industrial "partner." This is probably far more
meaningful to industrial investors than the traditional venture-capital
timing and ROI considerations.
6° ~. ~
Obviously, the_purchase of sufficient Cetus stock will entitle the
purchaser(s),:to.designate a member of the Board of Directors, which is
elected by cumulative voting.- At present, common shareholders elect
five, and preferred shareholders elect four members of the nine-member
. r
Board.
*The analogy to Xerox, Polaroid, and indeed the entire semiconductor
field is obvious.
. . r ,, . ,.~ _ .
-Y,f~i^K+Mr:i:-:.9..~'M..~....~~lArdi.r+.::=lS,..i.:h~ry3.k-.:'+~Y'.~.::.'Y.~Ari.'~w4.v~,....:....,
.:.:i.~ar.~.. .~.~.+f'4WXF-sre:ii`~I.CK .t.5~3.1.~f..yK3,M

._ . . ..t. a_ar:~.
..
. .....a..-.y~....
..~ ....~Y ...b .L},
t' JwC ' vP4t.. !_ .ti\r4 _,}; .t d .
. J.... . ., . ..
. ' . .~GJ. . l~ .. p~
~
O C? .,_
4
~0V `? ~:
~4~
Gp ~,
0"
Gp c~r~4
;O ~~tiG
{
r; .., . . ~.. . . . . ..~ =
{
`
'
n
~
. ~,. . r ~.. .,ti,.+~,+F:~ +ap~..m
t't,~s~ls.~r..~.+Fn.w;s,it:~s`:y.raa:~
it
r'-.,.:iu,e...:-eass..r.:.~:,Ld:,$...'~`..K,Z; ~::rr'~.A~i~i~i. wa,
sr.s:i~,~%:i'~.,F'1~'. ~
..
.. . ?.. .. :7 ~~:'~..r/ S.T~ .M:. . . .:~t~J:"~,~ ..,±~ .'S'._ ,i~ ..... _. ..
...'.~ -~...., .:1_
. . ~ C,. .. ..~. ;',~.oa
.i w . sJ ..:t~~ ~ ~-,
- .y'...=... . d~ - ..... _ w. . .r. ~.,_. ..~Y~.v.
. ~ r. _ _ _. . _ . . ,. ._
o'`

---
